Compugen (CGEN)
(Real Time Quote from BATS)
$1.65 USD
+0.02 (1.23%)
Updated Aug 8, 2024 09:56 AM ET
3-Hold of 5 3
C Value F Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Compugen Ltd. [CGEN]
Reports for Purchase
Showing records 21 - 40 ( 60 total )
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
BMY Collaboration Expanded For the Second Time This Year
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Bispecific Anti-TIGIT/Anti-PD-1 Antibody with AztraZeneca in the Clinic
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
2Q21: Building Momentum for the Triple Combination Hypothesis. Data in 4Q
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Bi-Pronged T-cell Boost against Solid Tumors in Clinic
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Updated Research on Compugen''s Programs at The SITC TIGIT Seminar
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Immunotherapy for PD-1-Refractory Patients may not be Far Fetched
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Clinical Activity in Relevant Doses Against Solid Tumors at ASCO
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T